The Pozen Digital Advisory Board
A conversation with Elizabeth A. Cermak, EVP, and Chief Commercial Officerat Pozen, Raj Amin, CEO and Co-Founder of HealthiNation, and Bonin Bough, Senior Global Director of Digital and Social Media, PepsiCo, about the who, what, why behind the Pozen Digital Advisory Board, an esteemed group of digital thought-leaders both in and outside of healthcare.
Pharma Marketing News Vol. 10, No. 9: 18 May 2011
Welcome to Volume 10, Issue #9 (18 MAY 2011) of Pharma Marketing News.
Limiting Bias in Commercially Supported CME
Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.
AstraZeneca Hosts First-Ever Twitter Chat
Despite dire predictions of 'PR failure,' the #rxsave Twitter chat hosted by @AstraZenecaUS on 15 February 2011 was a great success, which is pharma social media speak for 'did not crash and burn.' It was proof that a pharmaceutical company can indeed host meaningful Twitter chats.
PR & Interactive Agencies Vie for Pharma Social Media Campaign Crumbs
Should a PR firm or an interactive marketing agency be in charge of pharma social media campaigns?
Four Useful Lessons Pharma Can Learn from the Pfizer Facebook Hack
Pfizer's US corporate Facebook page was hacked by some 'Kiddies.' What should the industry learn from this experience?
Physicians Are Concerned About Pharma Support of CME, But Are Unwilling to Pay Their...
Talk about having your cake and eating it too! Commercial funding of continuing medical education (CME) and the potential for bias appear to concern many physicians, yet only a TINY MINORITY (7%) are willing to pay registration fees to eliminate or offset commercial funding sources, according to a report in the May 9, 2011, issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Adverse Event Reporting: A Missed Opportunity
When asked what the # 1 concern pharmaceutical marketers have regarding using social media, the adverse event reporting (AER) boogey man is cited most often. The urge to avoid this boogey man at all costs may have more to do with CEO compensation that with fears of rank-an-file marketers.
Consequences of eDetailing Technology
The Death of the Traditional Pharma Salesman and the Birth of the 'Sales Cyborg.' eDetailing in one form or another seems to be making a comeback since the recession hit the drug industry in 2007 and 2008. Which is the 'chicken' and which is the 'egg'? Did the uptick in adoption of eDetailing technology lead to the recent layoff of pharma reps or were reps laid off because of the economy and subsequently replaced by machines?
HCP Marketing Beyond the Physician
NPs, PAs, and even RNs are for the most part overlooked by the pharmaceutical industry, according to David Mittman, PA, president of Clinician 1. This article reviews the issue and includes tips for marketing to NPs and PAs.
